Abstract: The invention provides methods of treatment of acquired focal epilepsy in a human subject in need of the same, the methods comprising: (i) providing an expression vector encoding a polynucleotide sequence encoding LGI1, wherein the polynucleotide sequence is operably linked to a promoter suitable to drive expression of the LGI1 in human cells, (ii) administering the expression vector to the subject. Overexpressing LGI1 has been shown to affect excitatory neurons beyond the area of expression thereby targeting a large area and affecting neurons in an advantageously uniform manner.

Abstract: The invention provides expression vectors, nucleic acids, vector particles and methods of treatment involving these vector particles, comprising an engineered KCNA1 gene encoding an edited Kv1.1 potassium channel, as well as methods of confirming the presence of engineered KCNA1 mRNA in a cell. The features of the engineered KCNA1 gene combine to advantageously enhance the translation and activity of the Kv1.1 protein and improve detection of KCNA1 gene expression in a cell and can be used for example in the treatment of epilepsy and similar neurological disorders.